Status:
COMPLETED
Study to Evaluate the Abuse Potential of AZD7325 in Healthy Recreational Central Nervous System (CNS) Depressant Users
Lead Sponsor:
AstraZeneca
Conditions:
Recreational CNS Depressant Use
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to examine the abuse potential of AZD7325.
Eligibility Criteria
Inclusion
- Recreational CNS depressant use, defined as at least 10 lifetime occasions of non-medical use of drugs with depressant/sedative properties and at least 1 non-medical use in the year prior to screening
- Body mass index (BMI) within the range of 19.0 to 33.0 kg/m2, inclusive, and a minimum weight of 50.0 kg at screening
- Willing and able to abide by all study requirements and restrictions
Exclusion
- Unwillingness of inability to abstain from recreational drug use for the duration of the study from screening until follow-up
- Positive breath alcohol test prior to dosing
- Clinically significant abnormalities on physical examination, medical history, 12-lead ECG, vital signs, or safety laboratories
Key Trial Info
Start Date :
May 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2009
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00902772
Start Date
May 1 2009
End Date
September 1 2009
Last Update
September 23 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Toronto, Ontario, Canada